on cross-disciplinary global disability research.
To join the mailing list for this seminar series please e-mail your details to Ellie Cole.
Members of the department contribute to IGH public meetings which bring
together expertise on global health issues from all faculties within
Contact: Sarah Ball, Tel: (internal x82 72 2352)
2012 Seminar Series
Title: ‘Public health applications of cardiovascular genomics’
Speaker: Dr Michael Holmes
Date & Time: Friday 22nd June 1pm-2pm
Venue: G37 & G38
Over the past decade, genomic data have become readily available with many genetic loci now robustly identified with disease risk. The question now arises of how to translate this information into improved clinical care. Three distinct translational methods include: (i) personalized drug prescribing (pharmacogenetics); (ii) investigating the role of putative causal biomarkers in disease aetiology to improve biological understanding and validate new drug targets (Mendelian randomization), and; (iii) utility of genomic information to predict disease events.
The PhD is based on two of these three domains. First, I investigated the evidence base behind what has been considered a “prototype” pharmacogenetic test: CYP2C19 genotype testing to predict response to clopidogrel, a widely prescribed antiplatelet drug. Second, I used Mendelian randomization to investigate the role of secretory phospholipase A2 (sPLA2-IIA), an enzyme thought to be pro-atherogenic, in cardiovascular disease. Finally, I am investigating the role of alcohol in cardiovascular health using the gene ADH1B.
Michael obtained BSc (Hons) at St Andrews University, MBBS at University College London and Masters (Epidemiology) at London School of Hygiene and Tropical Medicine. His supervisors are Dr. Juan P Casas, Prof. Aroon Hingorani, and Prof. Mika Kivimaki. He is funded by a MRC Population Health Scientist Fellowship.
Page last modified on 12 sep 12 17:09